Pyruvate-conjugation of PEGylated liposomes for targeted drug delivery to retinal photoreceptors

[1]  M. Kähkönen,et al.  Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration , 2021, BMC Ophthalmology.

[2]  N. Schipper,et al.  Investigating Ex Vivo Animal Models to Test the Performance of Intravitreal Liposomal Drug Delivery Systems , 2021, Pharmaceutics.

[3]  Pádraig J. Mulholland,et al.  Intravitreal injections: past trends and future projections within a UK tertiary hospital , 2021, Eye.

[4]  K. Edwards,et al.  Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug delivery. , 2021, International journal of pharmaceutics.

[5]  K. Sandvig,et al.  Cellular uptake of nanoparticles: Involvement of caveolae? , 2021, Precision Nanomedicine.

[6]  T. Loftsson,et al.  Cytotoxicity of β-Cyclodextrins in Retinal Explants for Intravitreal Drug Formulations , 2021, Molecules.

[7]  François Paquet-Durand,et al.  Long-Term, Serum-Free Cultivation of Organotypic Mouse Retina Explants with Intact Retinal Pigment Epithelium. , 2020, Journal of visualized experiments : JoVE.

[8]  A. Urtti,et al.  Ocular barriers to retinal delivery of intravitreal liposomes: Impact of vitreoretinal interface. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[9]  E. Tarcsa,et al.  Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape. , 2020, Drug discovery today. Technologies.

[10]  C. Futter,et al.  Membrane trafficking in the retinal pigment epithelium at a glance , 2020, Journal of Cell Science.

[11]  J. Dean,et al.  Optimisation of glutathione conjugation to liposomes quantified with a validated HPLC assay. , 2019, International journal of pharmaceutics.

[12]  F. Otero-Espinar,et al.  Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration , 2019, Pharmaceutics.

[13]  P. Gaillard,et al.  Targeted brain delivery of methotrexate by glutathione PEGylated liposomes: How can the formulation make a difference? , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  Lei Shang,et al.  Ascorbate-conjugated nanoparticles for promoted oral delivery of therapeutic drugs via sodium-dependent vitamin C transporter 1 (SVCT1) , 2018, Artificial cells, nanomedicine, and biotechnology.

[15]  A. Ho,et al.  Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections. , 2018, American journal of ophthalmology.

[16]  Thomas Euler,et al.  Combination of cGMP analogue and drug delivery system provides functional protection in hereditary retinal degeneration , 2018, Proceedings of the National Academy of Sciences.

[17]  Qing Yao,et al.  Transporter-Guided Delivery of Nanoparticles to Improve Drug Permeation across Cellular Barriers and Drug Exposure to Selective Cell Types , 2018, Front. Pharmacol..

[18]  G. Wang,et al.  L-Carnitine-conjugated nanoparticles to promote permeation across blood–brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2 , 2017, Artificial cells, nanomedicine, and biotechnology.

[19]  H. Sánchez-Calderón,et al.  Müller glia and phagocytosis of cell debris in retinal tissue , 2017, Journal of anatomy.

[20]  T. Andresen,et al.  The diffusion dynamics of PEGylated liposomes in the intact vitreous of the ex vivo porcine eye: A fluorescence correlation spectroscopy and biodistribution study. , 2017, International journal of pharmaceutics.

[21]  Ji-Ho Park,et al.  Effective Retinal Penetration of Lipophilic and Lipid-Conjugated Hydrophilic Agents Delivered by Engineered Liposomes. , 2017, Molecular pharmaceutics.

[22]  V. Ganapathy,et al.  Dual targeting of l-carnitine-conjugated nanoparticles to OCTN2 and ATB0,+ to deliver chemotherapeutic agents for colon cancer therapy , 2017, Drug delivery.

[23]  D. Maussang,et al.  Glutathione conjugation dose-dependently increases brain-specific liposomal drug delivery in vitro and in vivo. , 2016, Drug discovery today. Technologies.

[24]  Jin Sun,et al.  Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting. , 2016, Colloids and surfaces. B, Biointerfaces.

[25]  Qingzhi Wu,et al.  Water-soluble l-cysteine-coated FePt nanoparticles as dual MRI/CT imaging contrast agent for glioma , 2015, International journal of nanomedicine.

[26]  D. Lamprou,et al.  Influence of cholesterol on liposome stability and on in vitro drug release , 2015, Drug Delivery and Translational Research.

[27]  B. Telfer,et al.  Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport , 2014, Molecular Cancer Therapeutics.

[28]  T. Rosenberg,et al.  Prevalence of Generalized Retinal Dystrophy in Denmark , 2014, Ophthalmic epidemiology.

[29]  S. Ren,et al.  Smart nanodevice combined tumor-specific vector with cellular microenvironment-triggered property for highly effective antiglioma therapy. , 2014, ACS nano.

[30]  C. Alexander,et al.  Uptake and transport of B12-conjugated nanoparticles in airway epithelium , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[31]  P. Diwan,et al.  β-Hydroxybutyric acid grafted solid lipid nanoparticles: a novel strategy to improve drug delivery to brain. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[32]  M. Ueffing,et al.  Retinitis pigmentosa: rapid neurodegeneration is governed by slow cell death mechanisms , 2013, Cell Death and Disease.

[33]  D. Sabatini,et al.  MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors , 2012, Nature Genetics.

[34]  E. Fattal,et al.  Liposomes for intravitreal drug delivery: a state of the art. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[35]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[36]  A. Halestrap,et al.  The monocarboxylate transporter family—Role and regulation , 2012, IUBMB life.

[37]  F. Sanz,et al.  A single‐molecule force spectroscopy nanosensor for the identification of new antibiotics and antimalarials , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  Bhumika Pandey,et al.  Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Preparation, Characterization, and in Vitro Release Study of Albendazole-encapsulated Nanosize Liposomes , 2022 .

[39]  A. Halestrap,et al.  AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7–10 , 2009, The Biochemical journal.

[40]  Joseph Kost,et al.  Ultrasound triggered release of cisplatin from liposomes in murine tumors. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[41]  M. Ueffing,et al.  PKG activity causes photoreceptor cell death in two retinitis pigmentosa models , 2009, Journal of neurochemistry.

[42]  K. Csaky,et al.  Investigating the Movement of Intravitreal Human Serum Albumin Nanoparticles in the Vitreous and Retina , 2009, Pharmaceutical Research.

[43]  Eberhart Zrenner,et al.  Photoreceptor Cell Death Mechanisms in Inherited Retinal Degeneration , 2008, Molecular Neurobiology.

[44]  M. Morris,et al.  The Role of Monocarboxylate Transporter 2 and 4 in the Transport of γ-Hydroxybutyric Acid in Mammalian Cells , 2007, Drug Metabolism and Disposition.

[45]  R. Schubert,et al.  Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. , 2006, Biochimica et biophysica acta.

[46]  Theresa M Allen,et al.  Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates , 2005, Clinical Cancer Research.

[47]  N. Osborne,et al.  Expression of monocarboxylate transporters in rat ocular tissues. , 2005, American journal of physiology. Cell physiology.

[48]  A. Kennan,et al.  Light in retinitis pigmentosa. , 2005, Trends in genetics : TIG.

[49]  Robert Gurny,et al.  Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. , 2003, Investigative ophthalmology & visual science.

[50]  T. Muramatsu,et al.  Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. , 2003, Investigative ophthalmology & visual science.

[51]  N. Philp,et al.  Identification of a unique monocarboxylate transporter (MCT3) in retinal pigment epithelium. , 1997, Biochemical and biophysical research communications.

[52]  J. Hollyfield,et al.  Endocytosis in the inner segment of rod photoreceptors: analysis of Xenopus laevis retinas using horseradish peroxidase. , 1987, Experimental eye research.

[53]  H. Romijn.  Development and advantages of serum‐free, chemically defined nutrient media for culturing of nerve tissue , 1988, Biology of the cell.